Procedures
AT ORASIS, WE PRIDE OURSELVES ON DELIVERING EXCEPTIONAL VISION CARE THAT TRULY CHANGES LIVES.
Resources
CXL provides long-term benefits for patients suffering from various vision conditions

Corneal cross-linking (CXL) is a procedure used to treat a condition called keratoconus, which is characterized by a progressive thinning and bulging of the cornea. During the corneal cross-linking procedure, the cornea is strengthened by creating new cross-links between collagen fibers in the corneal tissue.
This is achieved by applying riboflavin (vitamin B2) eye drops to the cornea and then exposing it to ultraviolet (UV) light. The riboflavin helps to enhance the cross-linking process when activated by the UV light. CXL helps to strengthen the cornea, the outermost layer of the eye, by stimulating the production of collagen fibers that provide structural support. This process has been shown to provide long-term benefits for patients suffering from various vision conditions, including keratoconus, a progressive disorder that causes thinning of the cornea. In this blog post, we will discuss how CXL can help to improve eyesight and provide a long-term solution for better vision.
The cross-linking procedure works by increasing the collagen cross-link density within the cornea, making it stiffer and more stable. This helps to halt the progression of keratoconus, preventing further thinning and bulging of the cornea. Corneal cross-linking is typically performed as an outpatient procedure under local anesthesia. The entire process usually takes about an hour. After the procedure, patients may experience temporary discomfort, light sensitivity, and blurred vision. The recovery period can vary, but it generally takes a few days to a few weeks for the vision to stabilize.
Who is a good candidate for CXL?
Corneal cross-linking (CXL) is recommended for patients with progressive keratoconus, a condition in which the cornea gradually thins and bulges into a cone shape. Keratoconus is a common cause of vision loss and discomfort, and CXL is a safe and effective treatment that can slow or even stop the progression of the condition.
Aside from patients with keratoconus, those with corneal ectasia following laser refractive surgery (such as LASIK) may also be good candidates for CXL. The procedure can also be considered for those with pellucid marginal degeneration and other forms of corneal ectasia.

It’s important to note that not all patients with keratoconus will require CXL. The decision to undergo CXL is typically made by an eye doctor after a comprehensive eye exam and a series of tests to assess the progression of the condition.
Overall, patients who are in good overall health, have a stable corneal condition, and have realistic expectations for the procedure are considered to be good candidates for CXL. However, it’s important to discuss the procedure in detail with your eye doctor to determine if it’s the right choice for you.
In the next section, we will explore the risks associated with CXL and how they can be minimized.